Synthetic data is moving from “privacy workaround” to core infrastructure for AI training and biomedical research. This week’s signal: generation is getting easier and more scalable, but evaluation, labeling, and provenance controls are not keeping pace.
A Scoping Review of Synthetic Data Generation by Language Models in Biomedical Research
An arXiv scoping review surveys 59 studies (2020–2025) using LLMs to generate synthetic data for biomedical applications. It finds prompt-based generation dominates (74.6%), and unstructured text is the main modality (78%), underscoring how quickly teams are using LLMs to “manufacture” clinical-style narratives and notes.
The review’s central critique is operational: evaluation remains inconsistent, with limited standardized protocols, which slows clinical adoption and makes cross-study comparisons fragile. For data leads, this reads like a governance backlog—how to validate utility, bias, and leakage when outputs are text-heavy and downstream tasks vary.
- Prompt-first pipelines are becoming the default in biomed; QA needs to adapt to text-centric synthetic datasets.
- Lack of standardized evaluation raises procurement and IRB friction for clinical research deployments.
- Teams should expect increasing scrutiny on transparency (generation method, prompts, and post-processing).
Synthetic Data: The New Data Frontier
The World Economic Forum’s September 2025 report frames synthetic data as a response to data scarcity, privacy constraints, and representativeness gaps across sectors. It also flags systemic risks—like data integrity concerns and model collapse—while proposing governance recommendations for developers, organizations, and regulators.
- Policy language is converging on “responsible use” controls: documentation, oversight, and risk management.
- Founders selling synthetic data tools should anticipate buyer requirements tied to governance checklists.
Synthetic Data in Health Economics and Outcomes Research
A peer-reviewed HEOR-focused article reviews how synthetic data can address privacy barriers, data insufficiency, and underrepresented populations—especially in rare disease research. The authors emphasize that HEOR has distinct requirements, and call for evaluation frameworks tailored to its contexts.
- Rare disease and equity use cases are a practical wedge, but require domain-specific validation norms.
- Compliance teams should treat “fit-for-purpose” evaluation as part of acceptable use, not an afterthought.
SynthLLM: Breaking the AI 'Data Wall' with Scalable Synthetic Data
Microsoft Research Asia introduced SynthLLM, positioned as a scalable way to generate synthetic training data from pretraining corpora across domains including healthcare, autonomous driving, education, and code generation—without manual labeling. The pitch is clear: synthetic data as a throughput tool, not just a privacy tool.
For engineering teams, the practical question shifts to provenance and quality assurance: what constraints exist on the source corpora, what filtering is applied, and how do you detect drift or contamination when scaling generation? Enterprise adoption will likely hinge on auditability as much as performance.
- Scalable generation changes cost curves, but increases the blast radius of weak provenance controls.
- Data teams should plan for dataset “lineage” artifacts (inputs, transformations, and intended use).
- Vendors will compete on evaluation tooling and reporting, not just generation speed.
GenAI Synthetic Data Create Ethical Challenges for Scientists
A PNAS study highlights integrity and ethics risks when GenAI-produced synthetic data is misrepresented as real, complicating reproducibility and trust in scientific outputs. The work points to the need for transparency and validation standards that make synthetic provenance explicit.
- Expect stronger norms (and potentially rules) around labeling synthetic datasets and documenting generation.
- Research orgs should update publication and data-sharing policies to prevent synthetic/real ambiguity.